These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 34652911)

  • 1. Exploration of a Nitromethane-Carbonylation Strategy during Route Design of an Atropisomeric KRAS
    Douglas JJ; Tatton MR; de Bruin D; Buttar D; Cook C; Dai K; Ferrer C; Leslie K; Morrison J; Munday R; Ronson TO; Zhao H
    J Org Chem; 2022 Feb; 87(4):2075-2086. PubMed ID: 34652911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations.
    Lanman BA; Parsons AT; Zech SG
    Acc Chem Res; 2022 Oct; 55(20):2892-2903. PubMed ID: 36178208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of
    Chen CY; Lu Z; Scattolin T; Chen C; Gan Y; McLaughlin M
    Org Lett; 2023 Feb; 25(6):944-949. PubMed ID: 36723667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium perchlorate-nitromethane-promoted alkylation of anilines with arylmethanols.
    Zhou J; Mao HF; Wang L; Zou JP; Zhang W
    Mol Divers; 2011 Nov; 15(4):849-55. PubMed ID: 21547437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative tandem nitrosation/cyclization of N-aryl enamines with nitromethane toward 3-(trifluoromethyl)quinoxalines.
    Yang ZJ; Liu CZ; Hu BL; Deng CL; Zhang XG
    Chem Commun (Camb); 2014 Dec; 50(93):14554-7. PubMed ID: 25308914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring Targeted Degradation Strategy for Oncogenic KRAS
    Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
    Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-ingestion of methanol and nitromethane: using falsely elevated creatinine as indicator for methanol antidote use.
    Leonard CP; Akhtar J
    Pediatr Crit Care Med; 2007 Jul; 8(4):392-3. PubMed ID: 17545934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
    Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
    Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is elevated creatinine a reliable marker for methanol toxicity in nitromethane-containing model fuel ingestions in children?
    Padmanabhan P; Spiller HA; Ross MP; Bosse GM
    Clin Toxicol (Phila); 2011 Jan; 49(1):45-7. PubMed ID: 21288151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitromethane interferes in assay of creatinine by the Jaffé reaction.
    De Leacy EA; Brown NN; Clague AE
    Clin Chem; 1989 Aug; 35(8):1772-4. PubMed ID: 2758650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of nitromethane concentration on ignition energy and explosion parameters in gaseous nitromethane/air mixtures.
    Zhang Q; Li W; Lin DC; He N; Duan Y
    J Hazard Mater; 2011 Jan; 185(2-3):756-62. PubMed ID: 20965653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
    Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newly Synthesized KRAS
    Cancer Discov; 2020 Mar; 10(3):341. PubMed ID: 31953242
    [No Abstract]   [Full Text] [Related]  

  • 17. Asymmetric carbon-carbon bond formation gamma to a carbonyl group: phosphine-catalyzed addition of nitromethane to allenes.
    Smith SW; Fu GC
    J Am Chem Soc; 2009 Oct; 131(40):14231-3. PubMed ID: 19772285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP carcinogenesis studies of 2,2-bis(bromomethyl)-1,3-propanediol, nitromethane, and 1,2,3-trichloropropane (cas nos. 3296-90-0, 75-52-5, and 96-18-4) in guppies (Poecilia reticulata) and medaka (Oryzias latipes) (Waterborne Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2005 Oct; (528):1-190. PubMed ID: 16362062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
    Nagasaka M; Li Y; Sukari A; Ou SI; Al-Hallak MN; Azmi AS
    Cancer Treat Rev; 2020 Mar; 84():101974. PubMed ID: 32014824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motor dysfunction following chronic exposure to a fluoroalkane solvent mixture containing nitromethane.
    Sandyk R; Gillman MA
    Eur Neurol; 1984; 23(6):479-81. PubMed ID: 6510448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.